Bullfrog AI publishes Cell Reports data supporting BF-114 for liver diseases; adds Dr. Lopa Mishra to advisory board

BullFrog AI Holdings, Inc.

Study led by Dr. Lopa Mishra published in Cell Reports provides mechanistic evidence for BF-114 target β2-spectrin (SPTBN1 siRNA) in obesity, MASLD, MASH, and HCC.
Findings show reducing β2-spectrin can halt progression of MASLD and MASH and reduce liver damage in animal models.
Dr. Lopa Mishra, a globally recognized liver disease expert, joined Bullfrog AI's Scientific Advisory Board to guide BF-114 development.
Bullfrog AI will use its bfLEAP AI platform to analyze single-cell data from animal models and human patients for further mechanistic insights.
BF-114 is an siRNA targeting SPTBN1, aimed at treating obesity-related liver diseases with high unmet need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.